Payment overview · 2025
General Payments
$316.93
15 reported records · 6 companies
Healthcare provider profile · identity verified
Mandy Katrice Lucas, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · NASHVILLE, GA · NPI 1346531662
Verified facts
What the public records show
CMS Open Payments records show Mandy Katrice Lucas, M.D. received $316.93 in general payments during 2025 across 15 reported records.
Ardelyx, Inc. accounted for 30.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $96.01 | 30.3% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $78.93 | 24.9% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $57.34 | 18.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $55.94 | 17.6% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.34 | 7.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $6.37 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $316.93 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $96.01 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $78.93 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $78.93 | 4 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $57.34 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $36.16 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.34 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $22.34 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $19.78 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $6.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 145 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
53 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
145 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
146 | 33 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 712 | 154 |
| Amlodipine Besylate | Amlodipine Besylate | 651 | 145 |
| Losartan Potassium | Losartan Potassium | 427 | 90 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 337 | 87 |
| Gabapentin | Gabapentin | 325 | 69 |
| Metoprolol Tartrate | Metoprolol Tartrate | 324 | 74 |
| Metformin Hcl | Metformin Hcl | 306 | 64 |
| Pantoprazole Sodium | Pantoprazole Sodium | 247 | 65 |
| Omeprazole | Omeprazole | 242 | 59 |
| Levothyroxine Sodium | Levothyroxine Sodium | 241 | 47 |
| Lisinopril | Lisinopril | 232 | 52 |
| Potassium Chloride | Potassium Chloride | 211 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 191 | 42 |
| Tramadol Hcl | Tramadol Hcl | 190 | 38 |
| Furosemide | Furosemide | 176 | 50 |
| Simvastatin | Simvastatin | 176 | 38 |
| Montelukast Sodium | Montelukast Sodium | 174 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 170 | 58 |
| Famotidine | Famotidine | 165 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 160 | 29 |
| Meloxicam | Meloxicam | 159 | 39 |
| Zolpidem Tartrate | Zolpidem Tartrate | 158 | 23 |
| Trulicity | Dulaglutide | 146 | 33 |
| Mounjaro | Tirzepatide | 145 | 21 |
| Carvedilol | Carvedilol | 141 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 138 | 25 |
| Pregabalin | Pregabalin | 136 | 25 |
| Clonidine Hcl | Clonidine Hcl | 132 | 28 |
| Nifedipine Er | Nifedipine | 123 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 118 | 34 |
| Allopurinol | Allopurinol | 116 | 26 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 110 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 109 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 107 | 27 |
| Sertraline Hcl | Sertraline Hcl | 102 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 97 | 18 |
| Metoprolol Succinate | Metoprolol Succinate | 96 | 22 |
| Trazodone Hcl | Trazodone Hcl | 92 | 22 |
| Alendronate Sodium | Alendronate Sodium | 91 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 89 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 84 | 23 |
| Ibuprofen | Ibuprofen | 84 | 35 |
| Alprazolam | Alprazolam | 81 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 79 | 20 |
| Valsartan | Valsartan | 78 | 23 |
| Eliquis | Apixaban | 75 | 19 |
| Atenolol | Atenolol | 74 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 73 | 17 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 71 | 24 |
| Ozempic | Semaglutide | 71 | 15 |
| Levetiracetam | Levetiracetam | 69 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 68 | 14 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 68 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 67 | 17 |
| Januvia | Sitagliptin Phosphate | 66 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 66 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 66 | 31 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 65 | 16 |
| Telmisartan | Telmisartan | 65 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 62 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 61 | 22 |
| Mirtazapine | Mirtazapine | 60 | 12 |
| Farxiga | Dapagliflozin Propanediol | 58 | suppressed |
| Ondansetron Odt | Ondansetron | 57 | 17 |
| Naproxen | Naproxen | 54 | 16 |
| Promethazine Hcl | Promethazine Hcl | 54 | suppressed |
| Jardiance | Empagliflozin | 53 | 13 |
| Myrbetriq | Mirabegron | 53 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 52 | suppressed |
| Linzess | Linaclotide | 52 | 13 |
| Sucralfate | Sucralfate | 52 | 11 |
| Glipizide | Glipizide | 49 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 47 | 37 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 47 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 45 | suppressed |
| Ezetimibe | Ezetimibe | 45 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 44 | 13 |
| Chlorthalidone | Chlorthalidone | 44 | 12 |
| Warfarin Sodium | Warfarin Sodium | 44 | suppressed |
| Amoxicillin | Amoxicillin | 43 | 36 |
| Donepezil Hcl | Donepezil Hcl | 42 | suppressed |
| Nystatin | Nystatin | 42 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 41 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 40 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 39 | 12 |
| Spironolactone | Spironolactone | 39 | suppressed |
| Celecoxib | Celecoxib | 38 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 38 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 11 |
| Lovastatin | Lovastatin | 36 | 11 |
| Topiramate | Topiramate | 36 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 35 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 35 | suppressed |
| Glimepiride | Glimepiride | 35 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 34 | suppressed |
| Fluconazole | Fluconazole | 33 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 32 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 31 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | suppressed |
| Bumetanide | Bumetanide | 29 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 28 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Prednisone | Prednisone | 27 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Estradiol | Estradiol | 26 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 25 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 24 | suppressed |
| Digoxin | Digoxin | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Lorazepam | Lorazepam | 23 | suppressed |
| Lactulose | Lactulose | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Azithromycin | Azithromycin | 21 | 20 |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Clonidine | Clonidine | 20 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Eszopiclone | Eszopiclone | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Clonazepam | Clonazepam | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | suppressed |
| Quviviq | Daridorexant Hcl | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | 16 |
| Finasteride | Finasteride | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 16 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Kerendia | Finerenone | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Verapamil Sr | Verapamil Hcl | 12 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Ssd | Silver Sulfadiazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $316.93 · 15 records | Ardelyx, Inc. | AIRSUPRA, BREZTRI, IBSRELA, MOUNJARO, OTEZLA, REPATHA, The Cologuard Plus Collection Kit, VOQUEZNA, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error